세계의 피부 홍반성 루푸스 시장 보고서(2025년)

Cutaneous Lupus Erythematosus Global Market Report 2025

US $ 4,490 ￦ 6,265,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,056,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,846,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

피부 홍반성 루푸스 시장 규모는 향후 수년간 연평균 11.7%의 연평균 복합 성장률(CAGR)로 2029년까지 39억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 중의 성장은 R&D 투자 증가, 규제 당국의 승인 및 지원, 고령화, 환자 교육 및 인식 제고 캠페인 강화, 세계 시장 확대에 기인합니다. 예측 기간의 주요 동향으로는 원격의료의 확대, 환자 모니터링 및 관리 강화, 헬스케어의 기술 통합, 맞춤형 의료 및 정밀의료의 성장, 유전체 및 단백질체학 기술의 활용 등이 있습니다.

피부 감염의 유병률 증가가 향후 피부 홍반성 루푸스(CLE) 시장의 성장을 촉진할 것으로 예상됩니다. 피부 감염은 박테리아, 곰팡이, 바이러스와 같은 미생물이 피부 내로 침입하여 증식하여 다양한 증상과 불편함을 유발하여 발생합니다. 이러한 감염은 면역 반응을 일으켜 신체가 감염에 대항하기 위해 염증을 유발하는데, CLE 환자의 경우 이러한 면역 반응 증가는 피부 세포를 표적으로 삼아 증상을 악화시킬 수 있습니다. 예를 들어 2022년 9월 영국의 국가 행정 기관인 UK Health Security Agency(UKHSA)에 따르면 피부 및 연조직 감염과 관련된 메티실린 내성 황색포도상구균(MRSA) 사례의 비율은 전년 대비 33.7%로 상승했습니다. 또한 2020년 4월부터 2021년 3월까지 회계연도 동안 MRSA 사례는 25.7% 증가했습니다. 그 결과, 피부 감염증의 발병률 증가는 피부 홍반성 루푸스 시장의 성장을 가속할 것으로 예상됩니다.

피부 홍반성 루푸스 시장의 주요 기업은 치료 효과를 높이고, 환자 결과를 개선하며, 보다 타겟팅되고 편리한 치료를 제공하기 위해 임상시험 솔루션을 개발하고 있습니다. 임상시험 솔루션의 이러한 혁신은 이 피부 질환에 대한 시험의 설계, 효능 및 결과를 개선하는 고급 방법론과 치료법을 개발하는 것을 목표로 하고 있습니다. 예를 들어 2024년 8월 호주에 본사를 둔 생명공학 기업 녹소팜(Noxopharm Ltd.)은 자가면역질환, 특히 피부 홍반성 루푸스(CLE) 치료를 위한 약물 후보물질 SOF-SKN의 첫 번째 인체 임상시험을 시작했습니다. 이번 임상은 2단계로 나누어 진행됩니다. 1단계는 안전성을 확인하면서 단회 투여하는 것이고, 2단계는 서로 다른 지원자 그룹에 여러 번 투여하여 각 단계별 안전성을 평가하는 것입니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 피부 홍반성 루푸스 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 용도 산업의 분석
• 세계의 피부 홍반성 루푸스 시장 : 성장률 분석
• 세계의 피부 홍반성 루푸스 시장 실적 : 규모와 성장, 2019-2024
• 세계의 피부 홍반성 루푸스 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 피부 홍반성 루푸스 TAM(Total Addressable Market)

제6장 시장 세분화

• 세계의 피부 홍반성 루푸스 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 급성
• 아급성
• 간헐
• 만성
• 세계의 피부 홍반성 루푸스 시장 : 약제 클래스별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 레티노이드
• 코르티코스테로이드
• 면역억제제
• 항말라리아약
• 기타 약물 클래스
• 세계의 피부 홍반성 루푸스 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 주사
• 국소
• 기타 투여 경로
• 세계의 피부 홍반성 루푸스 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 전문 클리닉
• 홈케어
• 기타 최종사용자
• 세계의 피부 홍반성 루푸스 시장, 급성의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 전신 홍반성 루푸스(SLE) 관련 ACLE
• 비전신성 ACLE
• 세계의 피부 홍반성 루푸스 시장, 아급성의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• SLE 관련 SCLE
• 약제 유발성 SCLE
• 세계의 피부 홍반성 루푸스 시장, 간헐성의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 경도 간헐성형
• 재발형
• 세계의 피부 홍반성 루푸스 시장, 만성질환의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 원판상 홍반성 루푸스(DLE)
• 루푸스 지방직염(LP)
• 종창성 루푸스 홍반성 루푸스
• 비후성 홍반성 루푸스

제7장 지역별·국가별 분석

• 세계의 피부 홍반성 루푸스 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 피부 홍반성 루푸스 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 피부 홍반성 루푸스 시장 : 경쟁 구도
• 피부 홍반성 루푸스 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 대기업과 혁신적 기업

• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Bausch Health Companies Inc.
• UCB S.A.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 피부 홍반성 루푸스 시장 2029 : 새로운 기회를 제공하는 국가
• 피부 홍반성 루푸스 시장 2029 : 새로운 기회를 제공하는 부문
• 피부 홍반성 루푸스 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁의 전략

제36장 부록

KSA

영문 목차

영문목차

Cutaneous lupus erythematosus (CLE) is a chronic autoimmune skin disease marked by inflammation that can cause various skin lesions, photosensitivity, and potential scarring. Often associated with systemic lupus erythematosus (SLE), CLE primarily affects the skin. The main goals of treatment are to reduce inflammation, manage symptoms, and prevent flare-ups.

The primary types of cutaneous lupus erythematosus include acute, subacute, intermittent, and chronic forms. Acute cutaneous lupus erythematosus (ACLE) is characterized by sudden and severe skin reactions, often triggered by sun exposure. Symptoms typically feature a distinctive 'butterfly' rash across the cheeks and nose, as well as red, scaly patches on other sun-exposed areas. Drug classes for treatment include retinoids, corticosteroids, immunosuppressants, antimalarial drugs, and others, with administration routes such as oral, injections, and topical applications. The end users of these treatments include hospitals, specialty clinics, homecare settings, and others.

The cutaneous lupus erythematosus market research report is one of a series of new reports from the business research company that provides cutaneous lupus erythematosus market statistics, including cutaneous lupus erythematosus industry global market size, regional shares, competitors with an cutaneous lupus erythematosus market share, detailed cutaneous lupus erythematosus market segments, market trends and opportunities, and any further data you may need to thrive in the cutaneous lupus erythematosus industry. This cutaneous lupus erythematosus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cutaneous lupus erythematosus market size has grown rapidly in recent years. It will grow from $2.24 billion in 2024 to $2.51 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to government and private funding, the expansion of healthcare infrastructure, increased awareness and education, enhanced support systems for patients, and the and the rising prevalence of autoimmune disorders.

The cutaneous lupus erythematosus market size is expected to see rapid growth in the next few years. It will grow to $3.91 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing research and development investments, regulatory approvals and support, an aging population, enhanced patient education and awareness campaigns, and global market expansion. Major trends in the forecast period include the expansion of telemedicine, enhanced patient monitoring and management, technological integration in healthcare, the growth of personalized and precision medicine, and the and the use of genomic and proteomic technologies.

The increasing prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market in the future. Skin infections occur when microorganisms such as bacteria, fungi, or viruses invade and multiply within the skin, causing various symptoms and discomfort. These infections trigger an immune response, leading to inflammation as the body attempts to combat the infection. In individuals with CLE, this heightened immune response can exacerbate symptoms by targeting the skin cells. For example, in September 2022, according to the UK Health Security Agency (UKHSA), a UK-based national executive agency, the proportion of Methicillin-resistant Staphylococcus aureus (MRSA) cases linked to skin and soft tissue infections rose to 33.7% in 2022 from the previous year. Additionally, MRSA cases increased by 25.7% during the financial year from April 2020 to March 2021. Consequently, the rising incidence of skin infections is expected to boost the growth of the cutaneous lupus erythematosus market.

Major companies in the cutaneous lupus erythematosus market are advancing clinical trial solutions to enhance treatment effectiveness, improve patient outcomes, and offer more targeted and convenient therapies. These innovations in clinical trial solutions aim to develop advanced methodologies and treatments that enhance the design, efficacy, and outcomes of trials for this skin condition. For example, in August 2024, Noxopharm Ltd., an Australia-based biotechnology company, launched the first-in-human clinical trial of its drug candidate, SOF-SKN, aimed at treating autoimmune diseases, specifically cutaneous lupus erythematosus (CLE). The trial will be conducted in two phases: the first involves administering a single dose with safety checks, while the second includes multiple doses across different volunteer groups, with safety evaluations at each stage.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition is expected to advance Amgen's objective of providing innovative treatments for rare diseases and strengthen its portfolio in inflammation therapeutics. Horizon Therapeutics plc, based in Ireland, is a biopharmaceutical company specializing in medicines for rare diseases, including lupus erythematosus.

Major companies operating in the cutaneous lupus erythematosus market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Allergan Inc., LEO Pharma A/S, Glenmark Pharmaceuticals Limited

North America was the largest region in the cutaneous lupus erythematosus market in 2024. The regions covered in the cutaneous lupus erythematosus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cutaneous lupus erythematosus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cutaneous lupus erythematosus market consists of revenues earned by entities by providing services such as diagnostic testing services, treatment administration services, patient monitoring, and management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cutaneous lupus erythematosus market also includes sales of pharmaceuticals, biologics, immunomodulators, diagnostic tests, and medical devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cutaneous Lupus Erythematosus Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cutaneous lupus erythematosus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cutaneous lupus erythematosus ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cutaneous lupus erythematosus market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Acute; Subacute; Intermittent; Chronic
• 2) By Drug Class: Retinoids; Corticosteroids; Immunosuppressants; Antimalarial Drugs; Other Drug Classes
• 3) By Route Of Administration: Oral; Injections; Topical; Other Routes Of Administration
• 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Acute: Systemic Lupus Erythematosus (SLE)-Associated ACLE; Non-Systemic ACLE
• 2) By Subacute: SLE-Associated SCLE; Drug-Induced SCLE
• 3) By Intermittent: Mild Intermittent Forms; Relapsing Forms
• 4) By Chronic: Discoid Lupus Erythematosus (DLE); Lupus Panniculitis (LP); Tumid Lupus Erythematosus; Hypertrophic Lupus Erythematosus
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cutaneous Lupus Erythematosus Market Characteristics

3. Cutaneous Lupus Erythematosus Market Trends And Strategies

4. Cutaneous Lupus Erythematosus Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cutaneous Lupus Erythematosus Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cutaneous Lupus Erythematosus PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cutaneous Lupus Erythematosus Market Growth Rate Analysis
• 5.4. Global Cutaneous Lupus Erythematosus Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cutaneous Lupus Erythematosus Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cutaneous Lupus Erythematosus Total Addressable Market (TAM)

6. Cutaneous Lupus Erythematosus Market Segmentation

• 6.1. Global Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute
• Subacute
• Intermittent
• Chronic
• 6.2. Global Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retinoids
• Corticosteroids
• Immunosuppressants
• Antimalarial Drugs
• Other Drug classes
• 6.3. Global Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injections
• Topical
• Other Routes of Administration
• 6.4. Global Cutaneous Lupus Erythematosus Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.5. Global Cutaneous Lupus Erythematosus Market, Sub-Segmentation Of Acute, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Lupus Erythematosus (SLE)-Associated ACLE
• Non-Systemic ACLE
• 6.6. Global Cutaneous Lupus Erythematosus Market, Sub-Segmentation Of Subacute, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SLE-Associated SCLE
• Drug-Induced SCLE
• 6.7. Global Cutaneous Lupus Erythematosus Market, Sub-Segmentation Of Intermittent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Intermittent Forms
• Relapsing Forms
• 6.8. Global Cutaneous Lupus Erythematosus Market, Sub-Segmentation Of Chronic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Discoid Lupus Erythematosus (DLE)
• Lupus Panniculitis (LP)
• Tumid Lupus Erythematosus
• Hypertrophic Lupus Erythematosus

7. Cutaneous Lupus Erythematosus Market Regional And Country Analysis

• 7.1. Global Cutaneous Lupus Erythematosus Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cutaneous Lupus Erythematosus Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cutaneous Lupus Erythematosus Market

• 8.1. Asia-Pacific Cutaneous Lupus Erythematosus Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cutaneous Lupus Erythematosus Market

• 9.1. China Cutaneous Lupus Erythematosus Market Overview
• 9.2. China Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cutaneous Lupus Erythematosus Market

• 10.1. India Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cutaneous Lupus Erythematosus Market

• 11.1. Japan Cutaneous Lupus Erythematosus Market Overview
• 11.2. Japan Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cutaneous Lupus Erythematosus Market

• 12.1. Australia Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cutaneous Lupus Erythematosus Market

• 13.1. Indonesia Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cutaneous Lupus Erythematosus Market

• 14.1. South Korea Cutaneous Lupus Erythematosus Market Overview
• 14.2. South Korea Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cutaneous Lupus Erythematosus Market

• 15.1. Western Europe Cutaneous Lupus Erythematosus Market Overview
• 15.2. Western Europe Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cutaneous Lupus Erythematosus Market

• 16.1. UK Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cutaneous Lupus Erythematosus Market

• 17.1. Germany Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cutaneous Lupus Erythematosus Market

• 18.1. France Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cutaneous Lupus Erythematosus Market

• 19.1. Italy Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cutaneous Lupus Erythematosus Market

• 20.1. Spain Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cutaneous Lupus Erythematosus Market

• 21.1. Eastern Europe Cutaneous Lupus Erythematosus Market Overview
• 21.2. Eastern Europe Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cutaneous Lupus Erythematosus Market

• 22.1. Russia Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cutaneous Lupus Erythematosus Market

• 23.1. North America Cutaneous Lupus Erythematosus Market Overview
• 23.2. North America Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cutaneous Lupus Erythematosus Market

• 24.1. USA Cutaneous Lupus Erythematosus Market Overview
• 24.2. USA Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cutaneous Lupus Erythematosus Market

• 25.1. Canada Cutaneous Lupus Erythematosus Market Overview
• 25.2. Canada Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cutaneous Lupus Erythematosus Market

• 26.1. South America Cutaneous Lupus Erythematosus Market Overview
• 26.2. South America Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cutaneous Lupus Erythematosus Market

• 27.1. Brazil Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cutaneous Lupus Erythematosus Market

• 28.1. Middle East Cutaneous Lupus Erythematosus Market Overview
• 28.2. Middle East Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cutaneous Lupus Erythematosus Market

• 29.1. Africa Cutaneous Lupus Erythematosus Market Overview
• 29.2. Africa Cutaneous Lupus Erythematosus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cutaneous Lupus Erythematosus Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cutaneous Lupus Erythematosus Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cutaneous Lupus Erythematosus Market Competitive Landscape And Company Profiles

• 30.1. Cutaneous Lupus Erythematosus Market Competitive Landscape
• 30.2. Cutaneous Lupus Erythematosus Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cutaneous Lupus Erythematosus Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca PLC
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Biogen Inc.
• 31.10. Bausch Health Companies Inc.
• 31.11. UCB S.A.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Aurobindo Pharma Limited
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Hikma Pharmaceuticals PLC

32. Global Cutaneous Lupus Erythematosus Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cutaneous Lupus Erythematosus Market

34. Recent Developments In The Cutaneous Lupus Erythematosus Market

35. Cutaneous Lupus Erythematosus Market High Potential Countries, Segments and Strategies

• 35.1 Cutaneous Lupus Erythematosus Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cutaneous Lupus Erythematosus Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cutaneous Lupus Erythematosus Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료